Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Biosimilars Market, by Application
1.4.2 Europe Biosimilars Market, by Type
1.4.3 Europe Biosimilars Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, Jun – 2022, Aug) Leading Players
Chapter 4. Europe Biosimilars Market by Application
4.1 Europe Oncology Diseases Market by Country
4.2 Europe Blood Disorders Market by Country
4.3 Europe Chronic & Autoimmune Diseases Market by Country
4.4 Europe Others Market by Country
Chapter 5. Europe Biosimilars Market by Type
5.1 Europe Monoclonal Antibodies Market by Country
5.2 Europe Granulocyte-Colony Stimulating Factor Market by Country
5.3 Europe Erythropoietin Market by Country
5.4 Europe Human Growth Hormone Market by Country
5.5 Europe Insulin Market by Country
5.6 Europe Others Market by Country
Chapter 6. Europe Biosimilars Market by Country
6.1 Germany Biosimilars Market
6.1.1 Germany Biosimilars Market by Application
6.1.2 Germany Biosimilars Market by Type
6.2 UK Biosimilars Market
6.2.1 UK Biosimilars Market by Application
6.2.2 UK Biosimilars Market by Type
6.3 France Biosimilars Market
6.3.1 France Biosimilars Market by Application
6.3.2 France Biosimilars Market by Type
6.4 Russia Biosimilars Market
6.4.1 Russia Biosimilars Market by Application
6.4.2 Russia Biosimilars Market by Type
6.5 Spain Biosimilars Market
6.5.1 Spain Biosimilars Market by Application
6.5.2 Spain Biosimilars Market by Type
6.6 Italy Biosimilars Market
6.6.1 Italy Biosimilars Market by Application
6.6.2 Italy Biosimilars Market by Type
6.7 Rest of Europe Biosimilars Market
6.7.1 Rest of Europe Biosimilars Market by Application
6.7.2 Rest of Europe Biosimilars Market by Type
Chapter 7. Company Profiles
7.1 Fresenius SE & Co. KGaA
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals and Trials:
7.1.5.2 Product Launches and Product Expansions:
7.1.5.3 Acquisition and Mergers:
7.2 Dr. Reddy’s Laboratories Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional & Segmental Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.3.5.2 Product Launches and Product Expansions:
7.3.5.3 Acquisition and Mergers:
7.4 Amgen, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.4.5.2 Product Launches and Product Expansions:
7.4.5.3 Acquisition and Mergers:
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Approvals and Trials:
7.5.5.3 Product Launches and Product Expansions:
7.6 Eli Lilly And Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 Merck & Co., Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expenses
7.7.5 Recent strategies and developments:
7.7.5.1 Product Launches and Product Expansions:
7.8 Novartis AG (Sandoz)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.8.5.2 Approvals and Trials:
7.9 Biocon Limited
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Partnerships, Collaborations, and Agreements:
7.9.2.2 Product Launches and Product Expansions:
7.9.2.3 Acquisition and Mergers:
7.10. Intas Pharmaceutical Ltd.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements:
7.10.2.2 Product Launches and Product Expansions:
Unique Offerings 